RGEN Jan 2025 210.000 call
| Previous close | 18.90 |
| Open | 6.70 |
| Bid | 6.90 |
| Ask | 7.90 |
| Strike | 210.00 |
| Expiry date | 2025-01-17 |
| Day's range | 6.70 - 6.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 325 |
- GuruFocus.com
Repligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst Projections
Detailed Analysis of Repligen's Financial Performance and Market Positioning
ZacksRepligen (RGEN) Misses Q1 Earnings Estimates
Repligen (RGEN) delivered earnings and revenue surprises of -3.45% and 1.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireRepligen Reports First Quarter 2024 Financial Results
Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-yearIncreased Filtration (non-COVID) revenue by 12% year-over-yearAchieved a nine-month book-to-bill ratio of 1.03 WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The compa
